RecruitingNCT06876883

MItral Regurgitation Risk Assessment and CLinical modElling

MItral Regurgitation Risk Assessment and CLinical modElling (MIRACLE Study)


Sponsor

Sun Yat-sen University

Enrollment

2,000 participants

Start Date

Jun 15, 2016

Study Type

OBSERVATIONAL

Conditions

Summary

Mitral regurgitation (MR) is a common valvular heart disease worldwide, and untreated severe MR is associated with an elevated risk of heart failure and mortality. According to causes, MR could be divided into primary or secondary MR. The risk factors of mortality or heart failure hospitalization in different types of MR patients are under intensive investigation. MItral Regurgitation risk Assessment and CLinical modElling (MIRACLE) study is a prospective cohort study including adult patients diagnosed with ≥ moderate MR during hospitalization. Comprehensive echocardiographic examination was conducted at baseline evaluating valvular heart disease severity, atrial and ventricular systolic/diastolic function, pulmonary artery systolic pressure (PASP), etc. We aim to evaluate the prognostic risk factors of patients with MR and construct a prognostic clinical model to guide clinical decision-making.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Patients diagnosed with ≥ moderate mitral regurgitation during hospitalization.
  • Aged over 18 yrs.

Exclusion Criteria1

  • Patients unable to provide written consent.

Locations(1)

The First Affiliated Hospital of Sun Yat-sen Univerity

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06876883


Related Trials